Schrodinger Reports Mixed 2025 Results: Strong Revenue Growth & Key Partnerships Offset Clinical Program Discontinuation & Restructuring
SDGR is trading near its 52-week low of $11.11 (6.0% above the low).
Summary
Schrodinger's 2025 annual report shows strong revenue growth and major new drug discovery collaborations, but also a full-year net loss, a significant clinical program discontinuation due to safety, and a company-wide restructuring.
Key Events · Earnings and Guidance · SDGR
-
Financial Performance Update
Reported total revenue of $255.9 million for 2025, a 23% increase from 2024, but a net loss of $103.3 million for the full year, an improvement from a $187.1 million net loss in 2024. Q4 2025 showed a net income of $32.5 million.
-
Clinical Program Discontinuation
Discontinued the SGR-2921 CDC7 inhibitor clinical development program in August 2025 due to safety concerns, including two emergent events where the drug was considered to have contributed to patient deaths.
-
Strategic Restructuring Implemented
Underwent a restructuring in May 2025, reducing overall headcount by approximately 7% (60 employees), incurring $3 million in charges, but expecting $30 million in annualized operating expense savings.
-
Major Drug Discovery Collaborations
Entered a research collaboration and license agreement with Novartis in November 2024, including a $150 million upfront payment and potential milestones up to $2.272 billion. Also expanded collaborations with Eli Lilly and Otsuka Pharmaceutical in early 2025.
Analysis · SDGR · Life Sciences
Schrodinger's annual report presents a complex financial and operational landscape. While the company achieved strong revenue growth and secured significant new collaborations, particularly the multi-billion dollar potential deal with Novartis, the discontinuation of the SGR-2921 clinical program due to safety concerns, including patient deaths, is a major setback for its proprietary pipeline. The restructuring and associated cost savings are a proactive measure to improve financial efficiency and cash burn, indicating management's response to ongoing losses. Investors should consider the long-term potential of the computational platform and partnerships against the inherent risks and challenges of drug development, especially clinical failures.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 36.1% of the 1753 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.04%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SDGR was trading at $11.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $869.2M. The 52-week trading range was $11.11 to $27.63. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.